Quantitative interpretation of human biomonitoring data.

[1]  T. Clarkson,et al.  Perinatal methylmercury poisoning in Iraq. , 1976, American journal of diseases of children.

[2]  L. Pohl,et al.  Mechanism of metabolic activation of chloroform by rat liver microsomes. , 1980, Biochemical pharmacology.

[3]  M. Andersen,et al.  Risk Assessment Extrapolations and Physiological Modeling , 1985, Toxicology and industrial health.

[4]  P J Lioy,et al.  Routes of chloroform exposure and body burden from showering with chlorinated tap water. , 1990, Risk analysis : an official publication of the Society for Risk Analysis.

[5]  R L Chinery,et al.  A compartmental model for the prediction of breath concentration and absorbed dose of chloroform after exposure while showering. , 1993, Risk analysis : an official publication of the Society for Risk Analysis.

[6]  Michael A. Gallo,et al.  Reconstruction of short-term multi-route exposure to volatile organic compounds using physiologically based pharmacokinetic models , 1994 .

[7]  H. J. Clewell,et al.  Pharmacokinetic dose estimates of mercury in children and dose-response curves of performance tests in a large epidemiological study , 1995 .

[8]  P. Georgopoulos,et al.  Biomarkers of environmental benzene exposure. , 1996, Environmental health perspectives.

[9]  Neil E. Klepeis,et al.  Descriptive statistics tables from a detailed analysis of the National Human Activity Pattern Survey (NHAPS) data , 1996 .

[10]  C P Weisel,et al.  Studies of Multiroute Exposure/Dose Reconstruction Using Physiologically Based Pharmacokinetic Models 1 , 1996, Toxicology and industrial health.

[11]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[12]  R. Calderon,et al.  Arsenic : exposure and health effects , 1997 .

[13]  L. Wallace.  Human Exposure and Body Burden for Chloroform and Other Trihalomethanes , 1997 .

[14]  A. Roy,et al.  Reconstructing week-long exposures to volatile organic compounds using physiologically based pharmacokinetic models. , 1998, Journal of exposure analysis and environmental epidemiology.

[15]  M. Hicks,et al.  Airborne Exposure to Arsenic Occurring in Coal Fly Ash , 1999 .

[16]  H J Clewell,et al.  Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. , 1999, Risk analysis : an official publication of the Society for Risk Analysis.

[17]  K. Krishnan,et al.  Molecular Structure-Based Prediction of the Toxicokinetics of Inhaled Vapors in Humans , 1999 .

[18]  P. Mayer.  Residential End Uses of Water , 1999 .

[19]  G. L. Kedderis,et al.  Metabolism of chloroform by cytochrome P450 2E1 is required for induction of toxicity in the liver, kidney, and nose of male mice. , 1999, Toxicology and applied pharmacology.

[20]  L. Backer,et al.  Household exposures to drinking water disinfection by-products: whole blood trihalomethane levels , 2000, Journal of Exposure Analysis and Environmental Epidemiology.

[21]  H J Clewell,et al.  Determination of a site-specific reference dose for methylmercury for fish-eating populations. , 2000, Toxicology and industrial health.

[22]  R A Corley,et al.  Physiologically based pharmacokinetic modeling of the temperature-dependent dermal absorption of chloroform by humans following bath water exposures. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[23]  H J Clewell,et al.  Evaluating noncancer effects of trichloroethylene: dosimetry, mode of action, and risk assessment. , 2000, Environmental health perspectives.

[24]  H J Clewell,et al.  Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. , 2000, Environmental health perspectives.

[25]  R Tardif,et al.  Evaluation of the health risk associated with exposure to chloroform in indoor swimming pools. , 2000, Journal of toxicology and environmental health. Part A.

[26]  C Springall,et al.  A biomarker approach to measuring human dietary exposure to certain phthalate diesters , 2001, Food additives and contaminants.

[27]  H J Clewell,et al.  Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. , 2001, The Science of the total environment.

[28]  H J Clewell,et al.  Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[29]  M. Lorber.  A pharmacokinetic model for estimating exposure of Americans to dioxin-like compounds in the past, present, and future. , 2002, The Science of the total environment.

[30]  Rebecca A Clewell,et al.  Pharmacokinetics of toxic chemicals in breast milk: use of PBPK models to predict infant exposure. , 2002, Environmental health perspectives.

[31]  Harvey J Clewell,et al.  A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. , 2001, Environmental health perspectives.

[32]  D. Baird,et al.  Reproducibility of urinary phthalate metabolites in first morning urine samples. , 2002, Environmental health perspectives.

[33]  P. Levallois,et al.  CANCER RISK ASSOCIATED WITH HOUSEHOLD EXPOSURE TO CHLOROFORM , 2002, Journal of toxicology and environmental health. Part A.

[34]  J. Valentin.  Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.

[35]  Jeffrey H Mandel,et al.  Human donor liver and serum concentrations of perfluorooctanesulfonate and other perfluorochemicals. , 2003, Environmental science & technology.

[36]  Melvin E Andersen,et al.  Dose-dependent transitions in mechanisms of toxicity: case studies. , 2004, Toxicology and applied pharmacology.

[37]  Timothy R. Church,et al.  Quantitative Evaluation of Perfluorooctanesulfonate (PFOS) and Other Fluorochemicals in the Serum of Children , 2004 .

[38]  Melvin E Andersen,et al.  Dose-dependent transitions in mechanisms of toxicity. , 2004, Toxicology and applied pharmacology.

[39]  Jeffrey H Mandel,et al.  Characterization of risk for general population exposure to perfluorooctanoate. , 2004, Regulatory toxicology and pharmacology : RTP.

[40]  M. Sohn,et al.  Reconstructing population exposures from dose biomarkers: inhalation of trichloroethylene (TCE) as a case study , 2004, Journal of Exposure Analysis and Environmental Epidemiology.

[41]  Jeffrey H Mandel,et al.  Serum concentrations of perfluorooctanesulfonate and other fluorochemicals in an elderly population from Seattle, Washington. , 2004, Chemosphere.

[42]  Harvey J Clewell,et al.  Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[43]  G. Carrier,et al.  Worker exposures to triclopyr: risk assessment through measurements in urine samples. , 2005, The Annals of occupational hygiene.

[44]  T. Starr,et al.  Exposure Reconstruction for the TCDD‐Exposed NIOSH Cohort Using a Concentration‐ and Age‐Dependent Model of Elimination , 2005, Risk analysis : an official publication of the Society for Risk Analysis.

[45]  D. Kalman,et al.  A physiologically based toxicokinetic model of inhalation exposure to xylenes in Caucasian men. , 2005, Regulatory toxicology and pharmacology : RTP.

[46]  M. Bouchard,et al.  Determination of Biological Reference Values for Chlorpyrifos Metabolites in Human Urine Using a Toxicokinetic Approach , 2005, Journal of occupational and environmental hygiene.

[47]  Kouji Harada,et al.  Renal clearance of perfluorooctane sulfonate and perfluorooctanoate in humans and their species-specific excretion. , 2005, Environmental research.

[48]  Alan H. Stern,et al.  A Revised Probabilistic Estimate of the Maternal Methyl Mercury Intake Dose Corresponding to a Measured Cord Blood Mercury Concentration , 2004, Environmental health perspectives.

[49]  P. Brambilla,et al.  Concentration-dependent TCDD elimination kinetics in humans: toxicokinetic modeling for moderately to highly exposed adults from Seveso, Italy, and Vienna, Austria, and impact on dose estimates for the NIOSH cohort , 2005, Journal of Exposure Analysis and Environmental Epidemiology.

[50]  C. C. Hodge,et al.  Glucuronidation patterns of common urinary and serum monoester phthalate metabolites , 2005, Archives of Toxicology.

[51]  James S Bus,et al.  Strategies to assess systemic exposure of chemicals in subchronic/chronic diet and drinking water studies. , 2006, Toxicology and applied pharmacology.

[52]  Robert Tardif,et al.  Development of Physiologically Based Toxicokinetic Models for Improving the Human Indoor Exposure Assessment to Water Contaminants: Trichloroethylene and Trihalomethanes , 2006, Journal of toxicology and environmental health. Part A.

[53]  Harvey J Clewell,et al.  Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys--probing the determinants of long plasma half-lives. , 2006, Toxicology.

[54]  Harvey J Clewell,et al.  Use of a Physiologically Based Pharmacokinetic Model to Identify Exposures Consistent With Human Biomonitoring Data for Chloroform , 2006, Journal of toxicology and environmental health. Part A.

[55]  Nathalie H Gosselin,et al.  Reconstruction of methylmercury intakes in indigenous populations from biomarker data , 2006, Journal of Exposure Science and Environmental Epidemiology.

[56]  A. Calafat,et al.  Perfluorochemicals in pooled serum samples from United States residents in 2001 and 2002. , 2006, Environmental science & technology.

[57]  Harvey J Clewell,et al.  Development of a Screening Approach to Interpret Human Biomonitoring Data on Volatile Organic Compounds: Reverse Dosimetry on Biomonitoring Data for Trichloroethylene , 2007, Risk analysis : an official publication of the Society for Risk Analysis.

[58]  Harvey J Clewell,et al.  Use of Markov Chain Monte Carlo Analysis with a Physiologically‐Based Pharmacokinetic Model of Methylmercury to Estimate Exposures in U.S. Women of Childbearing Age , 2007, Risk analysis : an official publication of the Society for Risk Analysis.

[59]  Harvey J Clewell,et al.  Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling , 2007, Journal of Exposure Science and Environmental Epidemiology.

[60]  S M Rappaport,et al.  Exposure reconstruction for reducing uncertainty in risk assessment: example using MTBE biomarkers and a simple pharmacokinetic model , 2007, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[61]  Harvey J Clewell,et al.  A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[62]  Gerhard Andreas Wiesmüller,et al.  Internal phthalate exposure over the last two decades--a retrospective human biomonitoring study. , 2007, International journal of hygiene and environmental health.

[63]  R A Becker,et al.  Biomonitoring equivalents: a screening approach for interpreting biomonitoring results from a public health risk perspective. , 2007, Regulatory toxicology and pharmacology : RTP.

[64]  Melvin E Andersen,et al.  Tissue exposures to free and glucuronidated monobutylyphthalate in the pregnant and fetal rat following exposure to di-n-butylphthalate: evaluation with a PBPK model. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[65]  Harvey J Clewell,et al.  Development and specification of physiologically based pharmacokinetic models for use in risk assessment. , 2008, Regulatory toxicology and pharmacology : RTP.